The U.S. Food and Drug Administration (FDA) has officially approved leucovorin, a synthetic form of vitamin B9, as a treatment for cerebral folate deficiency – a rare genetic condition affecting folate metabolism in the brain. This decision follows recent statements from Trump administration officials, including President Donald Trump, Secretary of Health and Human Services Robert F. Kennedy, Jr., and FDA chief Marty Makary, who previously promoted the drug as a potential treatment for autism. However, after scientific review, the FDA determined there is insufficient evidence to support its use for autism.
The Science Behind the Decision
The FDA’s approval is specifically for addressing folate deficiencies caused by genetic mutations in the FOLR1 gene. This condition, which may affect fewer than one in a million people, can result in neurological symptoms resembling some aspects of autism, such as communication difficulties. Autism, however, is a distinct neurodevelopmental disorder with complex and poorly understood causes that do not stem from a folate deficiency.
David Mandell, a professor of psychiatry at the University of Pennsylvania, emphasizes that “the data suggesting a link between folate deficiency and autism are outdated and weak.” The scientific consensus supports this view, with Helen Tager-Flusberg, a psychologist at Boston University, noting that the FOLR1 gene has never been associated with autism.
Political Influence and Off-Label Prescriptions
The FDA’s decision comes amid concerns over political interference in scientific processes. Despite the lack of evidence, Trump administration officials publicly advocated for leucovorin as an autism treatment, leading to a 71% surge in off-label prescriptions for children following those announcements. Off-label prescriptions mean the drug is being used for a condition it hasn’t been approved to treat.
Mandell warns that “Pandora’s box is already open,” meaning the initial hype has created lasting demand for the drug outside of its approved use. Families may have spent funds on unproven treatments when more effective interventions could have been pursued.
Implications and Future Outlook
The FDA’s decision clarifies that leucovorin is an appropriate treatment for cerebral folate deficiency, but does not extend to autism. The long-term impact on off-label prescriptions remains uncertain, but experts express concern that the premature promotion of the drug for autism may have misled families and diverted resources from evidence-based treatments.
The FDA’s decision highlights the importance of separating scientific evidence from political rhetoric, especially when it comes to public health. Misleading claims can have real consequences for patients and families seeking effective care.
The FDA’s decision is a reminder that scientific rigor must guide medical approvals, even when challenged by political agendas. The situation underscores the need for clear communication and public education regarding the actual benefits and limitations of medical treatments.
